AS362 - Advanced glycation end-products and risk of pancreatic cancer
Data Dictionaries and Study Documentation
This section displays all study-related data dictionaries and study-related files. The investigators for this study will upload the datasets, data dictionaries, and other study-related files. Study-related files will be made available to the public one year after the completion of the ancillary study, with the exception of the datasets, which will only be available to those with a Data Distribution Agreement. Those will be available to those with permission to download and will appear as a download link next to the data dictionary
Data Dictionaries
Name | Description |
|---|
Study Documents
Name | Description |
|---|---|
| Nameas362matchingsummary_30dec13.pdf | Description |
| Nameas362matchingsummary_additionalAim2Cases_12sep14.pdf | Description |
Related Papers
Low-fat dietary pattern and pancreatic cancer risk in the Women's Health Initiative dietary modification randomized controlled trial
BACKGROUND: Observational studies suggest that diet may influence pancreatic cancer risk. We investigated the effect of a low-fat dietary intervention on pancreatic cancer incidence. METHODS: The Women's Health Initiative Dietary Modification (WHI-DM) trial is a randomized controlled trial conducted in 48 835 postmenopausal women age 50 to 79 years in the United States between 1993 and 1998. Women were randomly assigned to the intervention group (n = 19 541), with the goal of reducing total fat ...
Related Studies: 362
Anti-hypertensive medication use, soluble receptor for glycation end products and risk of pancreatic cancer in the Women’s Health Initiative Study
Pancreatic cancer is the fourth leading cause of cancer death. Soluble receptor for glycation end products (sRAGE), which is modulated by anti-hypertensive (HT) medications, has been inversely associated with pancreatic cancer. However, the association between commonly used anti-HT medications and risk of pancreatic cancer is unknown. A total of 145,551 postmenopausal women from the Women Health Initiative (WHI) Study were included in analysis. Use of angiotensin converting enzyme inhibitors (AC...
Keywords: Pancreatic Cancer; Advanced Glycation End-Products; Pharmacoepidemiology; Gastroenterology; Metabolic Syndrome; Medications; Incidence
Related Studies: 362
A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women
Advanced glycation end products (AGEs) dysregulate adipokines and induce inflammation by binding to their adipocyte receptor (RAGE). Soluble RAGE (sRAGE) prevents AGEs/RAGE signaling. We performed a nested case-control study of the association between sRAGE, adipokines, and incident pancreatic cancer risk in the prospective Women's Health Initiative Study. We individually matched controls (n = 802) to cases (n = 472) on age, race, and blood draw date. We evaluated serum concentrations of sRAGE, ...
Keywords: Biomarker; Ccl2; Body Weight; Composite Biomarker; Pancreatic Cancer; Prospective; Srage
